Business Context and Reporting Period
Company: Phase III Medical, Inc. (formerly Corniche Group Incorporated)
Reporting Period: Fiscal year ended December 31, 2003
Business Overview: The Company is in a transitional phase, winding down its former internet-based extended warranty business ("run-off") while pursuing a new strategy in the medical and biotechnology sector. The new model involves providing capital and guidance to biotech companies in exchange for royalty interests on future product revenues. As of December 31, 2003, the Company had one employee and no cash-generating revenues from its new venture.
Key Financial Metrics
| Metric | 2003 | 2002 | 2001 |
|---|---|---|---|
| Revenues | $64,632 | $81,348 | $107,447 |
| Gross Profit | $21,024 | $20,783 | $36,773 |
| Operating Loss | $(894,329) | $(1,149,270) | $(1,606,101) |
| Net Loss (Attributable to Common) | $(1,067,987) | $(1,207,522) | $(2,080,714) |
| Cash and Cash Equivalents | $210,947 | $19,255 | $51,268 |
| Working Capital (Deficiency) | $(793,749) | $(81,843) | $1,085,000 |
| Total Stockholders' Deficit | $(1,502,774) | $(823,895) | $373,733 |
| Notes Payable | $400,000 | $125,000 | N/A |
Note: Revenues in 2003 were derived almost entirely from the run-off of deferred warranty contracts sold in prior years.
Material Changes vs. Prior Period
- Operating Loss Reduction: The operating loss decreased by approximately $255,000 (22%) compared to 2002, primarily due to reduced employee termination costs, legal fees, and travel expenses as the Company wound down its former operations.
- StrandTek Recovery: The Company recovered approximately $987,000 from personal guarantors of a defaulted $1.25 million loan to StrandTek International, Inc. This resulted in a realized loss of $150,000 recorded in 2003, compared to a $258,103 provision for uncollectible notes in 2002.
- Interest Expense Surge: Interest expense increased significantly to $214,897 in 2003 from $23,022 in 2002. This was driven by higher debt levels, default penalties on notes payable, and the reclassification of Series A preferred stock dividends as interest expense under new accounting standards (SFAS 150).
- Capital Raising: The Company raised $214,781 net from a private placement of common stock and $295,000 net from the sale of notes in 2003 to fund operations and the new business plan.
Outlook, Risks, and Management Commentary
Going Concern Uncertainty
The Company's auditors (Holtz Rubenstein & Co., LLP) have issued a qualified opinion regarding the Company's ability to continue as a going concern. The Company has a history of operating losses, a stockholders' deficit of approximately $1.5 million, and a working capital deficiency of $793,749. There is substantial doubt about its ability to sustain operations without additional financing.
New Business Strategy
Management is pursuing royalty interests in medical technologies. Key developments include:
- Parallel Solutions, Inc. (PSI): Signed a royalty agreement on December 12, 2003, to fund a bioshielding platform technology. The Company has a minimum commitment of $1,000,000, with $80,000 paid as of year-end.
- NeoStem, Inc.: Entered a letter of intent in January 2004 to fund an adult stem cell banking enterprise in exchange for revenue sharing. No definitive agreement has been finalized.
Liquidity and Financing
The Company is actively raising capital through an amended equity private placement (targeting up to $4 million) and the issuance of short-term promissory notes bearing interest rates up to 20%. As of March 8, 2004, the Company had sold an additional 400,000 shares for $40,000 and issued $75,000 in new notes. Management warns that there is no assurance of raising sufficient funds to meet obligations, including the remaining $680,000 commitment to PSI.
Risk Factors
- Regulatory Risk: Potential requirement to register as an investment company under the Investment Company Act of 1940.
- Development Risk: No assurance that the PSI technology or future ventures will achieve regulatory approval or commercial success.
- Debt Risk: Several notes payable are in default or subject to high default interest rates and conversion penalties.
Investor Verification Checklist
- Going Concern Status: Verify the Company's ability to secure the necessary capital to fund the $680,000 remaining commitment to PSI and cover ongoing operating losses.
- Debt Obligations: Review the status of the $400,000 in notes payable, specifically the $60,000 portion in default and the associated 20% interest rates and conversion penalties.
- Preferred Stock Liability: Confirm the treatment of the $681,174 Series A mandatorily redeemable convertible preferred stock and the $433,196 in accrued dividends, which are classified as liabilities.
- Revenue Realization: Assess the timeline for generating actual revenue from the new medical royalty strategy, as current revenues are solely from the run-off of discontinued warranty contracts.
- Legal Proceedings: Confirm the finality of the StrandTek settlement and the absence of other material pending litigation.